logo
Will $5,000 Invested in Amazon Stock Make You $100,000 in a Decade?

Will $5,000 Invested in Amazon Stock Make You $100,000 in a Decade?

Globe and Mail13 hours ago

Amazon (NASDAQ: AMZN) stock has fallen 3% year to date while the S&P 500 (SNPINDEX: ^GSPC) has advanced 3%. But Wall Street anticipates a stronger performance from the retail giant over the next year. The median target price among 71 analysts is $240 per share, which implies 13% upside from its current share price of $212.
Tariffs are a big reason the stock has struggled in 2025, but sentiment appears to be on the upswing since the Trump administration de-escalated trade tensions with China. A recent survey from Charles Schwab shows Amazon was the third most-popular stock among retail investors in May.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »
Can Amazon turn $5,000 invested today into $100,000 over the next decade? Here are my thoughts.
Amazon's strength in e-commerce, advertising, and cloud computing are reasons to own the stock
Amazon has a strong position in three growing industries. The company operates the most popular online marketplace worldwide as measured by traffic, and it is the largest online retailer as measured by revenue. Amazon is also the third-largest ad tech company, and Amazon Web Services (AWS) is the largest public cloud.
The investment thesis is simple: Amazon's strong position in those industries should drive double-digit sales growth annually through the end of the decade. I say that because those industries are expanding at a double-digit pace. The estimates below come from Grand View Research:
Retail e-commerce sales are projected to grow at 11.6% annually through 2030.
Ad tech spending is forecast to increase at 14.4% annually through 2030.
Cloud computing sales are projected to grow at 20.4% annually through 2030.
Additionally, Amazon should become more profitable over time as two tailwinds drive its margins higher. First, the company is building 1,000+ generative artificial intelligence (AI) applications to automate and optimize tasks like coding, customer service, inventory management, and logistics. It's also infusing warehouse robots with generative AI so human workers can instruct them in natural language.
Second, digital advertising and cloud computing services earn higher margins than retail. Amazon in the first quarter reported double-digit sales growth in its advertising and cloud segments versus single-digit sales growth in its retail segments. That means the high-margin revenue streams are increasing more quickly, which will lift its total profit margin over time.
As a caveat, Amazon could struggle with tariffs in the near term. About one-third of sellers on the marketplace are based in China, and those brands account for a material percentage of advertising revenue. However, to quote portfolio managers at Baron Capital, "The company has repeatedly proven its ability to navigate complex environments and emerge stronger."
Wall Street estimates Amazon's earnings will increase at 10% annually through 2026. That makes the current valuation of 35 times earnings look expensive, but I suspect analysts are underestimating the company. Amazon topped the consensus estimate by an average of 21% in the last six quarters. I think that trend will continue due to its strong position in three growing industries.
Amazon is a good investment, but the stock is unlikely to turn $5,000 into $100,000 in the next decade
Amazon stock must increase 20-fold (1,900%) to turn $5,000 into $100,000 during the next decade. Returns of that magnitude are possible, but they happen infrequently. In fact, only five stocks in the S&P 500 increased at least 20-fold during the last decade as of June 12, 2025. They are listed below:
However, I doubt Amazon can generate a 20-fold return in the next decade simply because the company is already worth $2.3 trillion. And multiplying that number by 20 would take its market value to $46 trillion, which is approximately what the entire S&P 500 is worth today. That seems an unlikely outcome.
Nevertheless, I think Amazon is a worthwhile long-term investment at its current price. The company has a strong position in three growing industries and a track record for beating Wall Street's earnings estimates. That combination led to Amazon stock outperforming the S&P 500 by 40 percentage points over the last three years, and I expect continued outperformance in the next three years.
Should you invest $1,000 in Amazon right now?
Before you buy stock in Amazon, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Amazon wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $655,255!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $888,780!*
Now, it's worth noting Stock Advisor 's total average return is999% — a market-crushing outperformance compared to174%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of June 9, 2025
Charles Schwab is an advertising partner of Motley Fool Money. John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Trevor Jennewine has positions in Amazon, Axon Enterprise, and Nvidia. The Motley Fool has positions in and recommends Advanced Micro Devices, Amazon, Axon Enterprise, and Nvidia. The Motley Fool recommends Charles Schwab and Fair Isaac and recommends the following options: short June 2025 $85 calls on Charles Schwab. The Motley Fool has a disclosure policy.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Trump pocketed over $57 million from crypto coin sales
Trump pocketed over $57 million from crypto coin sales

CTV News

time40 minutes ago

  • CTV News

Trump pocketed over $57 million from crypto coin sales

U.S. President Donald Trump speaks after signing a bill blocking California's rule banning the sale of new gas-powered cars by 2035, in the East Room of the White House, Thursday, June 12, 2025, in Washington. (AP Photo/Alex Brandon) New York — U.S. President Donald Trump pocketed more than $57 million from token sales by the crypto venture he and his sons helped launch last year, according to federal financial disclosure forms released by the White House. The more than 230-page document issued by the Office of Government Ethics, dated Friday, lists the US president's holdings including stocks, dividends, real estate and investment portfolios. It showed that Trump, who during his first presidential election campaign in 2016 broke with the long tradition of candidates publishing their income tax returns, raked in $57.4 million from the sale of World Liberty Financial tokens. Trump and his sons helped launch the cryptocurrency investment and lending platform ahead of last year's election, raising conflict of interest concerns especially after he went on to win. He lent his name to this new company and launched a 'Trump' memecoin in January, just hours before his inauguration. World Liberty Financial had issued 100 billion tokens, of which some 22.5 billion were allocated to the Trump-affiliated company DT Marks Defi. Once hostile to the crypto industry, Trump has since returning to power enthusiastically embraced the sector, taking significant steps to clear regulatory hurdles and making large-scale investments. Trump has, among other moves, appointed crypto advocate Paul Atkins to head the Securities and Exchange Commission (SEC). He has also established a federal 'Strategic Bitcoin Reserve' aimed at auditing the government's bitcoin holdings, which were mainly accumulated by law enforcement from judicial seizures. Cryptocurrencies now have 'a champion and an ally' in the White House, Vice President JD Vance said last month during a bitcoin conference in Las Vegas. The document also provides an overview of the royalties that Trump has received through the sale of branded products and licensing agreements around the world. For instance, he earned $2.8 million from watches and $2.5 million from perfumes and sneakers. His Mar-a-Lago club in Florida also generated over $50 million in income for the president. Trump's golf courses around the world also helped pad his coffers, allowing him to pocket $29.1 million from the one in West Palm Beach, and $110.4 from the one in Miami. The president also received a monthly retirement payment of $6,484 from the Screen Actors Guild (SAG). AFP

Viking Therapeutics Stock (VKTX): This Underrated Russell 2000 Gem Could Skyrocket 200%
Viking Therapeutics Stock (VKTX): This Underrated Russell 2000 Gem Could Skyrocket 200%

Globe and Mail

timean hour ago

  • Globe and Mail

Viking Therapeutics Stock (VKTX): This Underrated Russell 2000 Gem Could Skyrocket 200%

Viking Therapeutics (VKTX) is quickly emerging as one of the most promising biotech stocks in the small-cap Russell 2000 index. With Wall Street analysts projecting a potential upside of over 200%, the stock has captured the attention of growth-focused investors. Backed by a strong pipeline targeting obesity and liver diseases, Viking's innovative therapies could pave the way for major breakthroughs and significant shareholder returns. Confident Investing Starts Here: VKTX's Bullish Case Viking Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies targeting metabolic and endocrine disorders. Their pipeline includes promising candidates for treating obesity, non-alcoholic fatty liver disease (NAFLD), and muscle wasting. Understandably, clinical-stage biotech firms come with high risk. Their treatments might never make it through trials or reach the market, and even if they do, profits aren't guaranteed. The company currently has no approved products, no revenue, and runs at a loss. During times of market uncertainty, investors often shy away from companies like this. However, Viking Therapeutics stands out from many other biotech firms. It's working on treatments for several major health issues, especially in areas where better options are needed. One key focus is weight loss, a market that's been growing fast and still has a lot of room to expand. Viking's top drug candidate, VK2735, targets both GLP-1 and GIP receptors, a combination found in Eli Lilly's (LLY) Zepbound, the current market leader and only approved drug of its kind so far. Additionally, the company is seeing encouraging results from its mid-stage program VK2809, aimed at treating metabolic dysfunction-associated steatohepatitis (MASH). For context, MASH is a liver disease linked to obesity and becoming increasingly common. While the FDA only approved the first treatment for MASH last year, more approvals are expected shortly. Is Viking Therapeutics a Good Stock to Buy? Viking Therapeutics stock carries high risk, making it unsuitable for cautious investors. However, for those comfortable with volatility, a small position could offer strong long-term upside while limiting potential losses if the company fails. According to TipRanks, VKTX stock has received a Strong Buy consensus rating, with 13 Buys and one Hold assigned in the last three months. The average Viking Therapeutics stock price target is $90.7, suggesting a potential upside of nearly 217.32% from the current level. Year-to-date, VKTX stock has declined by almost 30%. See more VKTX analyst ratings

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store